This page shows the latest phentermine news and features for those working in and with pharma, biotech and healthcare.
developers. There is a handful of approved drug therapies – including GlaxoSmithKline’s/Roche’s lipase inhibitor, Xenical (orlistat), Eisai’s Belviq (lorcaserin) and Vivus Qsymia (phentermine/topiramate) – but none have been
But despite being third to market among the new generation of obesity therapies after Eisai and Arena's Belviq (lorcaserin) and Vivus' Qsymia (phentermine/topiramate), both approved 18 months ago, Orexigen
REMS are already in place for other 'lifestyle' drugs such as Vivus' Qsymia (phentermine/topiramate) for obesity and Pfizer's smoking cessation therapy Chantix (varenicline).
s Contrave (bupropion/naltrexone), Arena/Eisai's Belviq (lorcaserin) and Vivus' Qsymia (phentermine/topiramate), although for patients the monthly cost will fall depending on their insurance cover.
the US of three other drugs; Eisai and Arena's Belviq (lorcaserin), Vivus' Qsymia (phentermine/topiramate) and Orexigen's Contrave (naltrexone and bupropion).
new products - Eisai and Arena's Belviq (lorcaserin), Vivus' Qsymia (phentermine/topiramate) and Orexigen's Contrave (naltrexone and bupropion) in the last couple of years in the US and other world
More from news
Approximately 2 fully matching, plus 27 partially matching documents found.
shareholders became unhappy with the way Vivus handled the launch of its obesity drug Qsymia (phentermine/ topiramat).
More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.
A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...